Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 8.14
NAS:EDAP's Cash-to-Debt is ranked higher than
74% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. NAS:EDAP: 8.14 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:EDAP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.37  Med: 5.83 Max: No Debt
Current: 8.14
Equity-to-Asset 0.56
NAS:EDAP's Equity-to-Asset is ranked lower than
67% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. NAS:EDAP: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:EDAP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.41 Max: 1
Current: 0.56
0.25
1
Debt-to-Equity 0.09
NAS:EDAP's Debt-to-Equity is ranked lower than
99.99% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 0.29 vs. NAS:EDAP: 0.09 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:EDAP' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06  Med: 0.29 Max: 1.62
Current: 0.09
0.06
1.62
Piotroski F-Score: 4
Altman Z-Score: 2.98
WACC vs ROIC
2.78%
-7.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -2.37
NAS:EDAP's Operating Margin % is ranked lower than
58% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.45 vs. NAS:EDAP: -2.37 )
Ranked among companies with meaningful Operating Margin % only.
NAS:EDAP' s Operating Margin % Range Over the Past 10 Years
Min: -18.31  Med: -11.32 Max: 1.51
Current: -2.37
-18.31
1.51
Net Margin % -0.24
NAS:EDAP's Net Margin % is ranked higher than
80% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. NAS:EDAP: -0.24 )
Ranked among companies with meaningful Net Margin % only.
NAS:EDAP' s Net Margin % Range Over the Past 10 Years
Min: -53.64  Med: -13.01 Max: 10.79
Current: -0.24
-53.64
10.79
ROE % -0.44
NAS:EDAP's ROE % is ranked higher than
92% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. NAS:EDAP: -0.44 )
Ranked among companies with meaningful ROE % only.
NAS:EDAP' s ROE % Range Over the Past 10 Years
Min: -111.74  Med: -22.27 Max: 19.53
Current: -0.44
-111.74
19.53
ROA % -0.32
NAS:EDAP's ROA % is ranked higher than
90% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.49 vs. NAS:EDAP: -0.32 )
Ranked among companies with meaningful ROA % only.
NAS:EDAP' s ROA % Range Over the Past 10 Years
Min: -31.62  Med: -9.52 Max: 8.89
Current: -0.32
-31.62
8.89
ROC (Joel Greenblatt) % 36.95
NAS:EDAP's ROC (Joel Greenblatt) % is ranked higher than
91% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 6.15 vs. NAS:EDAP: 36.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:EDAP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -65.88  Med: -24.1 Max: 52.82
Current: 36.95
-65.88
52.82
3-Year Revenue Growth Rate -7.20
NAS:EDAP's 3-Year Revenue Growth Rate is ranked lower than
77% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. NAS:EDAP: -7.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:EDAP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.3  Med: -3.4 Max: 10.9
Current: -7.2
-17.3
10.9
GuruFocus has detected 1 Warning Sign with Edap TMS SA $NAS:EDAP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:EDAP's 30-Y Financials

Financials (Next Earnings Date: 2017-11-17 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

EDAP Guru Trades in Q3 2016

Robert Bruce 1,045,494 sh (unchged)
» More
Q4 2016

EDAP Guru Trades in Q4 2016

Robert Bruce 1,045,494 sh (unchged)
» More
Q1 2017

EDAP Guru Trades in Q1 2017

Robert Bruce 1,045,494 sh (unchged)
» More
Q2 2017

EDAP Guru Trades in Q2 2017

Robert Bruce 1,045,494 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with EDAP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:XPAR:QUA, XPAR:MKEA, XPAR:EOSI, XPAR:ALTHE, XPAR:ALCOR, XPAR:STNT, XPAR:EMG, XPAR:ALVMG, XPAR:ALSGD, XPAR:ALSPW, XPAR:ALIMP, XPAR:GBT, XPAR:DIM » details
Traded in other countries:EDA.Germany,
Headquarter Location:France
Edap TMS SA is a holding company. The Company through its divisions HIFU and UDS,develops, produces and markets minimally invasive medical devices for urological diseases. Its divisions operate in Europe, the Americas, Asia and the rest of the world.

Edap TMS SA was incorporated on December 3, 1979 as a Societe Anonyme organized under the laws of the Republic of France for 60 years from the date of incorporation. It is a holding Company and is responsible for providing common services to its subsidiaries, including preparation and consolidation of the financial statements for the group, complying with the requirements of various regulatory agencies and maintaining the listing of its publicly held securities. Its activity is organized in two divisions: HIFU and UDS. Through these two divisions, the Company develops, produces and markets minimally invasive medical devices, mainly for urological diseases. It's HIFU and UDS divisions operate in Europe, the Americas, Asia and the rest of the world. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. Its HIFU business is quite seasonal and generally linked to lengthy hospital decision and investment processes. In addition to developing, manufacturing and marketing HIFU devices, the HIFU division also generates revenues from leasing equipment, as well as from the sale of disposables, spare parts and maintenance services. Currently, the only commercial product of the Company utilizing HIFU technology is the Ablatherm, an ultrasound guided HIFU device for the treatment of organ-confined prostate cancer. As of December 31, 2013, the HIFU division's patent portfolio contained 36 patents consisting of 16 in the United States, 18 in the European Union and Japan and 2 in Israel and the rest of the world. The Company belongs to 18 groups of patents covering key technologies related to therapeutic ultrasound principles, systems and associated software. The UDS division's main business is producing and marketing devices, known as lithotripters, for the treatment of urinary tract stones by means of ESWL technology. In addition to its manufacturing and selling of lithotripters, the UDS division also generates revenues from the leasing of lithotripters, as well as from the sale of disposables, spare parts and maintenance services. The UDS division offers the Sonolith i-move to small and mid-size hospitals, while the Sonolith i-sys is offered to large hospitals that can afford a fully dedicated and integrated lithotripter. Ablatherm-HIFU device competes with all current treatments for localized tumors, which include surgery, brachytherapy, radiotherapy, cryotherapy and hormonotherapy. The Company and its products are regulated in the United States by the FDA under a number of statutes including the Federal Food, Drug and Cosmetic Act.

Ratios

vs
industry
vs
history
Forward PE Ratio 49.26
EDAP's Forward PE Ratio is ranked lower than
92% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 25.64 vs. EDAP: 49.26 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 2.99
EDAP's PB Ratio is ranked lower than
56% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. EDAP: 2.99 )
Ranked among companies with meaningful PB Ratio only.
EDAP' s PB Ratio Range Over the Past 10 Years
Min: 0.49  Med: 2.77 Max: 18.27
Current: 2.99
0.49
18.27
PS Ratio 2.20
EDAP's PS Ratio is ranked higher than
58% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.32 vs. EDAP: 2.20 )
Ranked among companies with meaningful PS Ratio only.
EDAP' s PS Ratio Range Over the Past 10 Years
Min: 0.31  Med: 1.6 Max: 4.74
Current: 2.2
0.31
4.74
EV-to-EBIT 14.76
EDAP's EV-to-EBIT is ranked higher than
77% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 24.67 vs. EDAP: 14.76 )
Ranked among companies with meaningful EV-to-EBIT only.
EDAP' s EV-to-EBIT Range Over the Past 10 Years
Min: -5776  Med: -4.15 Max: 290.1
Current: 14.76
-5776
290.1
EV-to-EBITDA 14.76
EDAP's EV-to-EBITDA is ranked higher than
61% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 17.99 vs. EDAP: 14.76 )
Ranked among companies with meaningful EV-to-EBITDA only.
EDAP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5776  Med: -4.15 Max: 290.1
Current: 14.76
-5776
290.1
EV-to-Revenue 1.65
EDAP's EV-to-Revenue is ranked higher than
64% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. EDAP: 1.65 )
Ranked among companies with meaningful EV-to-Revenue only.
EDAP' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.3  Med: 1.6 Max: 4.6
Current: 1.65
-0.3
4.6
Current Ratio 2.96
EDAP's Current Ratio is ranked higher than
55% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.64 vs. EDAP: 2.96 )
Ranked among companies with meaningful Current Ratio only.
EDAP' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 2.36 Max: 3.92
Current: 2.96
1.27
3.92
Quick Ratio 2.35
EDAP's Quick Ratio is ranked higher than
67% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. EDAP: 2.35 )
Ranked among companies with meaningful Quick Ratio only.
EDAP' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.16 Max: 3.51
Current: 2.35
1.07
3.51
Days Inventory 86.73
EDAP's Days Inventory is ranked higher than
74% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. EDAP: 86.73 )
Ranked among companies with meaningful Days Inventory only.
EDAP' s Days Inventory Range Over the Past 10 Years
Min: 86.73  Med: 107.9 Max: 136.7
Current: 86.73
86.73
136.7
Days Sales Outstanding 125.42
EDAP's Days Sales Outstanding is ranked lower than
75% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. EDAP: 125.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
EDAP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 102.76  Med: 182.24 Max: 249.93
Current: 125.42
102.76
249.93

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.70
EDAP's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. EDAP: -9.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EDAP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23  Med: -7.2 Max: 2.9
Current: -9.7
-23
2.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 3.92
EDAP's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 6.83 vs. EDAP: 3.92 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EDAP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.29  Med: 3.89 Max: 19.45
Current: 3.92
0.29
19.45
Price-to-Tangible-Book 3.32
EDAP's Price-to-Tangible-Book is ranked higher than
55% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 3.98 vs. EDAP: 3.32 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EDAP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.22  Med: 2.61 Max: 16.75
Current: 3.32
0.22
16.75
Price-to-Intrinsic-Value-Projected-FCF 0.54
EDAP's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
73% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. EDAP: 0.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
EDAP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.41  Med: 4.02 Max: 28.2
Current: 0.54
0.41
28.2
Price-to-Median-PS-Value 1.37
EDAP's Price-to-Median-PS-Value is ranked lower than
79% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. EDAP: 1.37 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EDAP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 0.66 Max: 3.74
Current: 1.37
0.16
3.74
Earnings Yield (Greenblatt) % 6.78
EDAP's Earnings Yield (Greenblatt) % is ranked higher than
88% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. EDAP: 6.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EDAP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -10375.1  Med: -2.3 Max: 189209.4
Current: 6.78
-10375.1
189209.4

More Statistics

Revenue (TTM) (Mil) $40.00
EPS (TTM) $ -0.02
Beta0.36
Short Percentage of Float0.00%
52-Week Range $2.25 - 3.85
Shares Outstanding (Mil)28.73 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 45 56 61 69
EPS ($) -0.04 0.06 0.12 0.19
EPS without NRI ($) -0.04 0.06 0.12 0.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}